THE ROLE OF IMMUNOTHERAPY IN SMALL CELL LUNG CANCER

Abstract

Despite permanent scientific activity and research, limited progress has been made in more than two decades in the treatment of small-cell lung cancer (SCLC). The prognosis of SCLC remains poor. SCLC is a very immunogenic tumor with high somatic mutation numbers, immunosuppressive status. According to the recently published clinical trials, two immune-checkpoint inhibitors – atezolizumab and durvalumab, significantly prolong overall survival in this disease without additional safety concerns.